Related references
Note: Only part of the references are listed.Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study
Rashmi K. Murthy et al.
CANCER RESEARCH (2022)
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
Neil T. Conlon et al.
BRITISH JOURNAL OF CANCER (2021)
MOUNTAINEER:open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).
John H. Strickler et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma-Trial in Progress
John H. Strickler et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
Ilana Schlam et al.
NPJ BREAST CANCER (2021)
Trastuzumab Blocks the Receiver Function of HER2 Leading to the Population Shifts of HER2-Containing Homodimers and Heterodimers
Jun Zhao et al.
ANTIBODIES (2021)
ASCO 2020: highlights in breast cancer
Rupert Bartsch
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY (2021)
Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
Sumanpreet Kaur et al.
INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY (2021)
Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy
Afshin Derakhshani et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
R. K. Murthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases
O. Metzger Filho et al.
ANNALS OF ONCOLOGY (2020)
HER2-positive advanced breast cancer treatment in 2020
Marcelle G. Cesca et al.
CANCER TREATMENT REVIEWS (2020)
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Nancy U. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
Bob T. Li et al.
CANCER DISCOVERY (2020)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Sandra M. Swain et al.
LANCET ONCOLOGY (2020)
Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
Anita Kulukian et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Novel HER2-targeted therapies for HER2-positive metastatic breast cancer
Siddharth Kunte et al.
CANCER (2020)
Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars
Megan E. Tesch et al.
DRUGS (2020)
Systemic therapy for metastatic HER2-positive breast cancer
Philip Bredin et al.
SEMINARS IN ONCOLOGY (2020)
Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
Xue Yang et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2020)
Cancer statistics for African Americans, 2019
Carol E. DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
SORLA regulates endosomal trafficking and oncogenic fitness of HER2
Mika Pietila et al.
NATURE COMMUNICATIONS (2019)
Breast cancer statistics, 2019
Carol E. DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
E. Krasniqi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Differences in Breast Cancer Survival by Molecular Subtypes in the United States
Nadia Howlader et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2018)
Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer
Renata Duchnowska et al.
CANCER TREATMENT REVIEWS (2018)
Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects
Mariana Brandao et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2018)
Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study
Rashmi Murthy et al.
LANCET ONCOLOGY (2018)
Mechanisms of receptor tyrosine kinase activation in cancer
Zhenfang Du et al.
MOLECULAR CANCER (2018)
Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-PositiveMetastatic Breast Cancer A Phase 1b Clinical Trial
Virginia F. Borges et al.
JAMA ONCOLOGY (2018)
Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
Babak Nami et al.
CANCERS (2018)
Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy
Patricia M. R. Pereira et al.
NATURE COMMUNICATIONS (2018)
Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis
Yixiao Feng et al.
GENES & DISEASES (2018)
Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
Katsuhiko Nakatsukasa et al.
BREAST CANCER (2017)
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
N. Masuda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Current challenges in the management of breast cancer brain metastases
Ciara C. O'Sullivan et al.
SEMINARS IN ONCOLOGY (2017)
Breast Cancer: Multiple Subtypes within a Tumor?
Syn Kok Yeo et al.
TRENDS IN CANCER (2017)
Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)
Stacy L. Moulder et al.
CLINICAL CANCER RESEARCH (2017)
Alcohol consumption and breast cancer risk by estrogen receptor status: in a pooled analysis of 20 studies
Seungyoun Jung et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2016)
Abstract B152: Clinical pharmacokinetics of an improved tablet formulation of ONT-380 in HER2+ metastatic breast cancer patients
Alex C. Vo et al.
MOLECULAR CANCER THERAPEUTICS (2016)
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Jennifer L. Hsu et al.
CANCER AND METASTASIS REVIEWS (2016)
Efficacy results of a phase lb study of ONT-380, a CNS-penetrant TKI, in combination with T-DM1 in HER2+metastatic breast cancer (MBC), including patients (pts) with brain metastases.
Virginia F. Borges et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Active cigarette smoking and risk of breast cancer
Chelsea Catsburg et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Treatment of HER2-positive breast cancer
Maria Cristina Figueroa-Magalhaes et al.
BREAST (2014)
Trastuzumab emtansine: mechanisms of action and drug resistance
Mark Barok et al.
BREAST CANCER RESEARCH (2014)
The HER2 Signaling Network in Breast Cancer-Like a Spider in its Web
A. Dittrich et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2014)
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
Elisavet Paplomata et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2014)
Dietary Fat in Breast Cancer Survival
Nour Makarem et al.
ANNUAL REVIEW OF NUTRITION, VOL 33 (2013)
ARRY-380, a potent, small molecule inhibitor of ErbB2, increases survival in intracranial ErbB2+xenograft models in mice
Victoria Dinkel et al.
CANCER RESEARCH (2012)
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
Devika Gajria et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2011)
Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US
Kathleen A. Cronin et al.
CANCER INVESTIGATION (2010)
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Teemu T. Junttila et al.
CANCER CELL (2009)
The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies
Jaclyn A. Freudenberg et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2009)
Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2
Stefania Varchetta et al.
CANCER RESEARCH (2007)
ErbB receptors: from oncogenes to targeted cancer therapies
Hongtao Zhang et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
Maurizio Scaltriti et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Taxanes for adjuvant treatment of early breast cancer
T. Ferguson et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2007)
Exploiting the PI3K/AKT pathway for cancer drug discovery
BT Hennessy et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Docetaxel in the treatment of breast cancer: current experience and future prospects
JM Nabholtz et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2005)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata et al.
CANCER CELL (2004)
P27kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells
R Nahta et al.
CANCER RESEARCH (2004)
Alcohol, tobacco and breast cancer -: collaborative reanalysis of individual data from 53 epidemiological studies, including 58515 women with breast cancer and 95067 women without the disease
V Beral et al.
BRITISH JOURNAL OF CANCER (2002)
Share Paper
